Jefferies Group’s Whitehawk Therapeutics WHWK Stock Holding History

Jefferies Group’s Portfolio WHWK Stock Details WHWK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-667	Closed	-$9K	–	2924
2019 Q1	$9K	Buy	+667	New	+$28.7K	﹤0.01%	2267

Other funds holding WHWK

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Jefferies Group's WHWK Position: Q2 2019 in Review

Jefferies Group sold out of Whitehawk Therapeutics (WHWK) in Q2 2019, closing a stake of 667 shares — an estimated $9K sold.

Jefferies Group first reported a position in WHWK in Q1 2019 and held it in 1 quarter. The position peaked at $9K in Q1 2019. 24 funds tracked by Wall St. Rank hold WHWK as of Q2 2019.

Jefferies Group reported no remaining Whitehawk Therapeutics position as of Q2 2019 after selling out during the quarter.
Jefferies Group sold 667 Whitehawk Therapeutics shares in Q2 2019, an estimated $9K.
Jefferies Group first reported a position in Whitehawk Therapeutics in Q1 2019 and held it in 1 quarter.
Jefferies Group's Whitehawk Therapeutics position peaked at $9K in Q1 2019.
24 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2019.

Based on Jefferies Group's 13F filing for Q2 2019, filed 14 Aug 2019.